GlassScriptPhysician profile
Gregory M Terry
NPI 1972501773
$10,555.50
in general payments reported to CMS, 2019-2025
46 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,092 · 2020: $1,206 · 2021: $2,304 · 2022: $1,337 · 2023: $1,019 · 2024: $1,508 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,615.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,480.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,243.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,160.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $789.36 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $715.13 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $656.02 | 2019-2025 | |
| Amarin Pharma, INC. | $365.37 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $356.61 | 2019-2022 | |
| Esperion Therapeutics, INC. | $318.55 | 2020-2025 | Nexletol |
| Astellas Pharma US INC | $303.22 | 2019-2025 | Myrbetriq, Veozah |
| Amgen INC. | $298.54 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $237.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $236.51 | 2019-2025 | Belsomra, Steglatro, Steglujan |
| Sanofi-Aventis U.S. LLC | $199.40 | 2019-2025 | |
| Abbvie INC. | $180.66 | 2021-2023 | Ubrelvy |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Terry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.